Neurocrine Biosciences的NBI-1117568在精神分裂症的2期研究中显示出症状改善，没有严重的副作用。 Neurocrine Biosciences' NBI-1117568 in Phase 2 for schizophrenia shows symptom improvement with no serious side effects.

经由Nxera Pharma合作,神经生理科学公司报告了NBI-1117568在精神分裂症成年人中的积极的第二期数据. Neurocrine Biosciences reports positive Phase 2 data for NBI-1117568 in adults with schizophrenia, partnered with Nxera Pharma. 药物候选人的症状明显改善,没有严重的副作用。 The drug candidate showed significant improvement in symptoms and no serious side effects. 公司股份减少,可能与林业发展局最近关于另一种药物的决定有关。 Shares of the company decreased, potentially related to a recent FDA decision on another drug.